

JJP Biologics obtains positive in vivo preclinical melanoma data and continues development of JJP-1008, a first-in-class anti-CD270 checkpoint inhibitor

JJP Biologics confirms the mechanism of action and immunostimulatory activity of JJP-1008, a potential first-in-class therapeutic anti-CD270 monoclonal antibody. JJP-1008 selectively inhibits the immunosuppressive activity of the CD270 receptor, an immune checkpoint involved in the progression of a variety of cancers, including melanoma, pancreatic, and colon cancers.

June 10, 2025

Warsaw, Poland – In a humanized mouse model of melanoma (CDX/NOG), JJP Biologics confirmed the immunostimulatory activity and mechanism of action of JJP-1008. It was shown that after repeated intravenous administrations, the development of an aggressive and destructive form of melanoma was significantly inhibited. Moreover, JJP-1008 decreased progressive cachexia and in addition, the analysis of tumor tissue confirmed increased infiltration of CD4+ and CD8+ T cells, resulting in a transition from a state of immunosuppression to activation of the immune response.

In addition, it was demonstrated that high expression of CD270 in the tumor can be considered a potential mechanism of escape and resistance in melanoma. Switching the role of tumor defense against the immune system to CD270 leads to patients becoming unresponsive to PD-1 and PD-L1 inhibitors. There are currently no approved therapies that simultaneously block immunosuppressive CD272 (BTLA) and CD160 signaling while still allowing immune activation through CD258 (LIGHT) binding to CD270.

The potential of JJP-1008 has been validated in computational simulations, in vitro studies, and in vivo proof-of-concept studies. With the investigational medicinal product currently being prepared for GMP manufacturing, the project will enter clinical trials upon completion of in vivo toxicology studies.

About JJP-1008

JJP-1008 is a first-in-class IgG4-κ CD270 (HVEM) immune checkpoint inhibitor monoclonal antibody being developed for personalized cancer treatment. High CD270 expression on cancer cells suppresses the immune response, leading to poor prognosis. JJP-1008 binds to an epitope of CD270, which inhibits the regulatory signaling and enables strong activation of the immune response to fight cancer. In metastatic melanoma, CD270 expression is mutually exclusive with PD-L1 and is linked to resistance against PD1-PD-L1 inhibitors. To address this, JJP Biologics is developing a companion diagnostic to identify patients with elevated CD270 expression, who are most likely to benefit from JJP-1008. Beyond metastatic melanoma, JJP Biologics is investigating the potential of JJP-1008 in a range of solid tumors and leukemia.

The JJP-1008 project is co-financed from the state budget by the Polish Medical Research Agency (No: 2022/ABM/05/00015).

JJP BIOLOGICS

JJP Biologics is a privately funded, clinical stage biotechnology company that specializes in the development of therapeutic monoclonal antibodies accompanied by companion diagnostics for personalized treatments. JJP Biologics pursues the development of its own product candidates as well as projects executed in cooperation with scientific partners. By targeting specific immune pathways, the company's products have broad applications in autoimmune diseases and cancer. JJP Biologics' current product pipeline includes the most advanced JJP-1212, a first-in-class anti-CD89 antagonizing monoclonal antibody for the treatment of various autoimmune and fibrotic diseases, and JJP-1008, a first-in-class CD270 immune checkpoint inhibiting monoclonal antibody, for the treatment of various oncological indications.

For further information, please contact: info@jjpbiologics.com

Follow us on LinkedIn: *Be a smart goose*   <https://lnkd.in/eZV3ZbS9>